<DOC>
	<DOCNO>NCT00296959</DOCNO>
	<brief_summary>A phase II double blind trial evaluate effect AMPA , glutamte antagonist , topiramate levodopa-induced dyskinesia Parkinson 's disease</brief_summary>
	<brief_title>Topiramate Treatment Levodopa-Induced Dyskinesia Parkinson 's Disease</brief_title>
	<detailed_description>The propose study proof-of-concept , Phase II , randomize , double-blind , placebo-controlled , crossover trial ass anti-dyskinetic property topiramate patient PD bothersome levodopa-induced dyskinesia . Patients randomize receive tablet either placebo topiramate double-blind , crossover design use randomization table . Following completion first arm study taper washout phase , patient receive topiramate placebo crossover design treatment duration . The dose topiramate slowly escalate twice week tolerate . If patient tolerate high dose , dose reduce previously tolerate dose . Clinical assessment arm study include follow : 1 . Investigator-rated dyskinesia severity ( Levodopa challenge ) : Anti-parkinsonian medication hold 12 hour prior test . At time assessment , patient receive morning dose either topiramate placebo usual morning levodopa dose . Patients videotape prior follow medication administration , dyskinesia severity subsequently rat blinded investigator . Levodopa challenge conduct treatment arm ( baseline ) completion treatment arm . 2 . Subject-rated dyskinesia severity : Dyskinesia severity rat patient use several validate method ( Lang-Fahn Activities Daily Living Dyskinesia scale , Clinical Global Impression , Unified Parkinson 's Disease Rating Scale , home dyskinesia diary ) . Rating scale complete time levodopa challenge 2-week interval . Dyskinesia diary complete 3 day prior levodopa challenge . 3 . Assessment parkinsonism : Parkinsonian disability assess use UPDRS baseline evaluation completion treatment arm well bi-weekly visit . 4 . Safety tolerability assessment : During course titration phase , patient assess clinic 2-week interval , sooner indicate . A general physical examination include blood pressure , pulse , weight well detailed question regard possible adverse event tolerability complete . The Epworth Sleepiness Scale complete visit . Telephone contact make alternate week assess occurrence adverse event discuss titration schedule . Patients able reach physician time via pager event difficulty encounter schedule contact time . In addition , safety monitoring , laboratory test include urinalysis , clinical chemistry ( sodium , potassium , chloride , bicarbonate , BUN , creatinine ) , CBC differential , liver function test follow . These study evaluate begin end treatment arm mid-way dose escalation phase . A baseline EKG obtain , repeat EKGs obtain completion treatment arm . Results study aid development large Phase III clinical trial . From propose trial , information regard anti-dyskinetic efficacy topiramate obtain , tolerability PD patient population determine .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>UK PD Society Brain Bank criterion diagnosis idiopathic PD . Patients stable levodopainduced dyskinesia present great 25 % day ( Unified Parkinson 's Disease Rating Scale ( UPDRS ) , item 32 , rating &gt; 2 ) moderately completely disable ( UPDRS item 33 , rating &gt; 2 ) . All antiparkinsonian medication must stable least one month prior study enrollment . Include prior surgery PD Hoehn Yahr score 5 `` '' History nephrolithiasis Renal impairment Liver disease Pregnancy Premenopausal females male use adequate contraception Cognitive impairment ( Mini Mental State Exam score le 24 ) History glaucoma seizure Use antiepileptic drug Amantadine Carbonic anhydrase inhibitor Digoxin Metformin Or illicit drug</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Dyskinesia</keyword>
	<keyword>AMPA receptor antagonist</keyword>
</DOC>